Here are the 10-Q quarterly reports from VSee Health Inc WTS 29 (VSEEW) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow VSEEW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VSEEW filings page.
VSee Health, Inc. operates a telehealth services business centered on iDoc and reports continued losses and liquidity pressure for the quarter ended June 30, 2026. From continuing operations, revenue rose to $1.56 million for the quarter and $3.44 million for the first six months of 2026, up from $1.06 million and $2.25 million in the prior-year periods, but gross margin compressed and operating expenses increased, leading to a six‑month loss from continuing operations of $4.34 million.
Including discontinued operations, the company recorded net income driven by the May 31, 2026 divestiture of VSee Lab to former co‑CEO Milton Chen, recognizing a $4.17 million gain and cancelling 2,870,069 common shares. Cash fell sharply to $454,151 from $5.05 million at year‑end, with $2.50 million of operating cash outflows from continuing operations in the first half. Total assets were $16.73 million and total liabilities $9.14 million, leaving equity of $7.59 million. Management states that recurring losses, an accumulated deficit of $84.17 million, and limited liquidity raise substantial doubt about the company’s ability to continue as a going concern, despite past funding through debt and equity and ongoing efforts to improve its position.
VSee Health, Inc. reported first‑quarter 2026 revenue of $3.16 million, compared with $3.32 million in the prior‑year quarter. Gross margin was $1.20 million while operating expenses rose to $4.17 million, leading to a net operating loss of $2.97 million.
Net loss narrowed to $2.60 million versus $3.96 million a year earlier, helped by a $367,809 gain on extinguishment of financial liabilities and a $143,040 gain from changes in fair value of financial instruments. Basic and diluted loss per share was $0.05 on a weighted average of 47.9 million shares.
Cash declined to $1.35 million from $5.27 million at December 31, 2025, with operating activities using $2.45 million of cash in the quarter. The company ended the period with total assets of $19.0 million, liabilities of $12.7 million, and stockholders’ equity of $6.32 million, alongside an accumulated deficit of $85.0 million. Management states that recurring losses and liquidity conditions raise substantial doubt about VSee Health’s ability to continue as a going concern.